Literature DB >> 7537361

Association of phosphatidylinositol 3-kinase with SHC in chronic myelogeneous leukemia cells.

D Harrison-Findik1, M Susa, L Varticovski.   

Abstract

Expression of p210 BCR/abl oncoprotein transforms hematopoietic cells. P210 BCR/abl tyrosine kinase induces tyrosine phosphorylation of Shc, and activation of p21ras and PI 3-Kinase. Here we show that PI 3-Kinase associates with Shc in cells transformed by BCR/abl oncoprotein. Immunoprecipitation of Shc from cells expressing p210 BCR/abl had 7.5-fold increase in PI 3-Kinase activity compared to parental cells. Tyrosine phosphorylated Shc specifically bound to the C-SH2 domain of the p85 subunit of PI 3-Kinase. The p85 SH3 domain also interacted with Shc in cell lysates from parental and transformed cells. The binding of p85 SH3 domain to Shc was substantially higher in BCR/abl transformed than in parental cells. Phenylphosphate blocked p85 SH2 mediated association with Shc but enhanced the binding of the p85 SH3 domain to Shc. The N-terminal proline-rich region of Shc between A263 and N273 specifically blocked the interaction of p85 SH3 domain with Shc. Our results indicate that PI 3-Kinase interacts with Shc directly in hematopoietic cells which express p210 BCR/abl oncoprotein.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7537361

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

1.  Negative regulation of PI 3-kinase by Ruk, a novel adaptor protein.

Authors:  I Gout; G Middleton; J Adu; N N Ninkina; L B Drobot; V Filonenko; G Matsuka; A M Davies; M Waterfield; V L Buchman
Journal:  EMBO J       Date:  2000-08-01       Impact factor: 11.598

2.  CD3-epsilon overexpressed in prothymocytes acts as an oncogene.

Authors:  B Wang; J She; M Salio; D Allen; E Lacy; N Lonberg; C Terhorst
Journal:  Mol Med       Date:  1997-01       Impact factor: 6.354

Review 3.  Inhibition of Ras-mediated signaling pathways in CML stem cells.

Authors:  Jessika Bertacchini; Neda Ketabchi; Laura Mediani; Silvano Capitani; Sandra Marmiroli; Najmaldin Saki
Journal:  Cell Oncol (Dordr)       Date:  2015-10-12       Impact factor: 6.730

4.  Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.

Authors:  T Skorski; A Bellacosa; M Nieborowska-Skorska; M Majewski; R Martinez; J K Choi; R Trotta; P Wlodarski; D Perrotti; T O Chan; M A Wasik; P N Tsichlis; B Calabretta
Journal:  EMBO J       Date:  1997-10-15       Impact factor: 11.598

5.  Distinctive regulation of v-Src-associated phosphatidylinositol 3-kinase during PC12 cell differentiation.

Authors:  B Haefner; M C Frame
Journal:  Biochem J       Date:  1997-12-01       Impact factor: 3.857

6.  Phosphatidylinositol 3-kinase p85{alpha} subunit-dependent interaction with BCR/ABL-related fusion tyrosine kinases: molecular mechanisms and biological consequences.

Authors:  Shu-Yue Ren; Elisabeth Bolton; M Golam Mohi; Andrea Morrione; Benjamin G Neel; Tomasz Skorski
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

Review 7.  Hepatocyte growth factor/scatter factor-induced intracellular signalling.

Authors:  K A Stuart; S M Riordan; S Lidder; L Crostella; R Williams; G G Skouteris
Journal:  Int J Exp Pathol       Date:  2000-02       Impact factor: 1.925

8.  Caveolin 1-mediated regulation of receptor tyrosine kinase-associated phosphatidylinositol 3-kinase activity by ceramide.

Authors:  W Zundel; L M Swiersz; A Giaccia
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

9.  Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2.

Authors:  R R Beerli; D Graus-Porta; K Woods-Cook; X Chen; Y Yarden; N E Hynes
Journal:  Mol Cell Biol       Date:  1995-12       Impact factor: 4.272

10.  An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259.

Authors:  T Pene-Dumitrescu; L F Peterson; N J Donato; T E Smithgall
Journal:  Oncogene       Date:  2008-09-15       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.